A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
Pishesha N, Harmand TJ, Rothlauf PW, Praest P, Alexander RK, van den Doel R, Liebeskind MJ, Vakaki MA, McCaul N, Wijne C, Verhaar E, Pinney W 3rd, Heston H, Bloyet LM, Pontelli MC, Ilagan MXG, Jan Lebbink R, Buchser WJ, Wiertz EJHJ, Whelan SPJ, Ploegh HL.
Pishesha N, et al.
Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2116147118. doi: 10.1073/pnas.2116147118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34654739
Free PMC article.